New and future immunomodulatory therapy in type 1 diabetes

Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting β cells of the pancreas and requires lifelong insu...

Full description

Saved in:
Bibliographic Details
Published inTrends in molecular medicine Vol. 18; no. 3; pp. 173 - 181
Main Authors Tooley, James E, Waldron-Lynch, Frank, Herold, Kevan C
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2012
Subjects
Animals
biologics
Clinical Trials as Topic
Diabetes Mellitus, Type 1 - immunology
Diabetes Mellitus, Type 1 - therapy
Humans
Immunologic Factors - immunology
Immunologic Factors - therapeutic use
Immunomodulation
immunotherapy
metabolic therapy
Nutrition Therapy
Pathology
type 1 diabetes
type 1 diabetes
biologics
metabolic therapy
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting β cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia – the result of insulin deficiency – include secondary endorgan complications. Over the past two decades our increased understanding of the pathogenesis of this disease has led to the development of new immunomodulatory treatments. None have yet received regulatory approval, but this report highlights recent progress in this area.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1471-4914
1471-499X
DOI:10.1016/j.molmed.2012.01.001